|Systematic (IUPAC) name|
|Molecular mass||293.361 g/mol|
|(what is this?)|
S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids.
S-40503 is a SARM that shows good functional selectivity for bone tissue, and has relatively little effect on muscle mass and no observable effect on the prostate gland. In animal studies it was shown to increase both bone mineral density and biomechanical strength of femoral cortical bone, and at low doses showed anabolic effects only on bone tissue, while at higher doses both bone and muscle growth were affected, yet prostate gland enlargement was not seen at any dose tested. The lack of virilizing effects means that S-40503 may even be suitable for use in women, which would be a substantial advantage over existing drugs as women tend to be more likely to suffer from osteoporosis, and are generally contraindicated from taking anabolic steroids due to the risk of side effects such as masculinisation and hirsutism. Since these promising initial studies, no further data about S-40503 has been published by Kaken, and it is thought that rather than being developed for human use itself, S-40503 may be more likely to be used as a lead compound for the development of novel derivatives with similar bone anabolic effects, but longer in vivo half-life and better bioavailability.
Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to anabolic steroids but with significantly less side effects. For this reason, SARMs have already been banned by the World Anti-Doping Agency since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed.
- Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today. 2007 Mar;12(5-6):241-8. doi:10.1016/j.drudis.2007.01.003 PMID 17331889
- Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biological and Pharmaceutical Bulletin. 2003 Nov;26(11):1563-9. doi:10.1248/bpb.26.1563 PMID 14600402
- Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research. 2006 Aug;23(8):1641-58. PMID 16841196
- Thevis M, Kohler M, Schlörer N, Kamber M, Kühn A, Linscheid MW, Schänzer W. Mass spectrometry of hydantoin-derived selective androgen receptor modulators. Journal of Mass Spectrometry. 2008 May;43(5):639-50. doi:10.1002/jms.1364 PMID 18095383
- Thevis M, Kohler M, Thomas A, Maurer J, Schlörer N, Kamber M, Schänzer W. Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Analytical and Bioanalytical Chemistry. 2008 May;391(1):251-61. doi:10.1007/s00216-008-1882-6 PMID 18270691